Polyglutamine Toxicity Is Controlled by Prion Composition and Gene Dosage in Yeast

School of Biology, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
PLoS Genetics (Impact Factor: 7.53). 04/2012; 8(4):e1002634. DOI: 10.1371/journal.pgen.1002634
Source: PubMed


Polyglutamine expansion causes diseases in humans and other mammals. One example is Huntington's disease. Fragments of human huntingtin protein having an expanded polyglutamine stretch form aggregates and cause cytotoxicity in yeast cells bearing endogenous QN-rich proteins in the aggregated (prion) form. Attachment of the proline(P)-rich region targets polyglutamines to the large perinuclear deposit (aggresome). Aggresome formation ameliorates polyglutamine cytotoxicity in cells containing only the prion form of Rnq1 protein. Here we show that expanded polyglutamines both with (poly-QP) or without (poly-Q) a P-rich stretch remain toxic in the presence of the prion form of translation termination (release) factor Sup35 (eRF3). A Sup35 derivative that lacks the QN-rich domain and is unable to be incorporated into aggregates counteracts cytotoxicity, suggesting that toxicity is due to Sup35 sequestration. Increase in the levels of another release factor, Sup45 (eRF1), due to either disomy by chromosome II containing the SUP45 gene or to introduction of the SUP45-bearing plasmid counteracts poly-Q or poly-QP toxicity in the presence of the Sup35 prion. Protein analysis confirms that polyglutamines alter aggregation patterns of Sup35 and promote aggregation of Sup45, while excess Sup45 counteracts these effects. Our data show that one and the same mode of polyglutamine aggregation could be cytoprotective or cytotoxic, depending on the composition of other aggregates in a eukaryotic cell, and demonstrate that other aggregates expand the range of proteins that are susceptible to sequestration by polyglutamines.

Download full-text


Available from: Piotr A Mieczkowski
  • Source
    • "Prion variants that do not cause toxicity on their own may become toxic in combination with other factors. For example, endogenous prions, such as [PIN + ] and/or [PSI + ] (Gokhale et al., 2005; Gong et al., 2012; Kochneva-Pervukhova et al., 2012; Zhao et al., 2012), promote aggregation and toxicity of expanded polyQ constructs in the yeast huntingtin model. Overproduction of Sup35 (Chernoff et al., 1992; Derkatch et al., 1997; Vishveshwara et al., 2009) or Rnq1 (Douglas et al., 2008; Stein & True, 2011; Treusch & Lindquist, 2012) is toxic to prion-containing cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prions are self-perpetuating protein isoforms that cause fatal and incurable neurodegenerative disease in mammals. Recent evidence indicates that a majority of human proteins involved in amyloid and neural inclusion disorders possess at least some prion properties. In lower eukaryotes, such as yeast, prions act as epigenetic elements, which increase phenotypic diversity by altering a range of cellular processes. While some yeast prions are clearly pathogenic, it is also postulated that prion formation could be beneficial in variable environmental conditions. Yeast and mammalian prions have similar molecular properties. Crucial cellular factors and conditions influencing prion formation and propagation were uncovered in the yeast models. Stress-related chaperones, protein quality control deposits, degradation pathways and cytoskeletal networks control prion formation and propagation in yeast. Environmental stresses trigger prion formation and loss, supposedly acting via influencing intracellular concentrations of the prion-inducing proteins, and/or by localizing prionogenic proteins to the prion induction sites via heterologous ancillary helpers. Physiological and environmental modulation of yeast prions points to new opportunities for pharmacological intervention and/or prophylactic measures targeting general cellular systems rather than the properties of individual amyloids and prions. This article is protected by copyright. All rights reserved.
    Full-text · Article · Nov 2013 · FEMS microbiology reviews
  • Source
    • "Although the Q25 htt variant (corresponding to a normal polyQ length) did not aggregate, insoluble inclusion formation increased with an increase in the polyQ length (Krobitsch and Lindquist 2000), recapitulating results obtained in cultured mammalian cells and animal models (Apostol et al. 2003, 2006; Woodman et al. 2007). The correlation between aggregation and toxicity of htt fragments in yeast was found to be dependent on the sequences flanking the polyglutamine stretches as well as on the existence of specific interacting proteins of the yeast strain expressing it, in particular the prion composition of the cell (Meriin et al. 2002; Duennwald et al. 2006a, b; Gong et al. 2012). Specifically, the htt exon 1 with expanded polyQ tracts was shown to impair protein homeostasis of the ER (Duennwald and Lindquist 2008) and endocytosis (Meriin et al. 2003, 2007), cause transcriptional deregulation (Hughes et al. 2001), increase ROS production by affecting mitochondrial function and morphology (Giorgini et al. 2005; Sokolov et al. 2006; Solans et al. 2006), induce activation of apoptotic pathways (Sokolov et al. 2006), and cause cell cycle dysfunction (Sokolov et al. 2006; Bocharova et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), or prion diseases, are known for their intimate association with protein misfolding and aggregation. These disorders are characterized by the loss of specific neuronal populations in the brain and are highly associated with aging, suggesting a decline in proteostasis capacity may contribute to pathogenesis. Nevertheless, the precise molecular mechanisms that lead to the selective demise of neurons remain poorly understood. As a consequence, appropriate therapeutic approaches and effective treatments are largely lacking. The development of cellular and animal models that faithfully reproduce central aspects of neurodegeneration have been crucial for advancing our understanding of these diseases. Approaches involving the sequential use of different model systems, starting with simpler cellular models and ending with validation in more complex animal models, resulted in the discovery of promising therapeutic targets and small molecules with therapeutic potential. Within this framework, the simple and well-characterized eukaryote Saccharomyces cerevisiae, also known as budding yeast, is being increasingly used to study the molecular basis of several neurodegenerative disorders. Yeast provides an unprecedented toolbox for the dissection of complex biological processes and pathways. Here, we summarize how yeast models are adding to our current understanding of several neurodegenerative disorders. This article is protected by copyright. All rights reserved.
    Full-text · Article · Apr 2013 · Journal of Neurochemistry
  • Source
    • "Perhaps, there is a certain threshold concentration for a misfolded protein where it can no longer be efficiently recruited to a single site and neutralized; proteins with efficient targeting would only cause cytotoxic effects upon accumulation above this threshold. Alternatively, 'aggresome' targeting does not ameliorate cytotoxicity in yeast in the presence of specific prions (Gong et al., 2012). Cellular proteins involved in managing misfolded protein species can be anticipated to mitigate cytotoxicity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) are linked to the accumulation of specific protein aggregates in affected regions of the nervous system. SOD1, TDP-43, FUS and optineurin (OPTN) proteins were identified to form intraneuronal inclusions in ALS patients. In addition, mutations in OPTN are associated with both ALS and glaucoma. Since the pathological role of OPTN in neuronal degeneration remains unresolved, we created a yeast model to study its potential for aggregation and toxicity. We observed that both wild type and disease-associated mutants of OPTN form toxic non-amyloid aggregates in yeast. Similar to reported cell culture and mouse models, the OPTN E50K mutant shows enhanced toxicity in yeast, implying a conserved gain-of-function mechanism. Furthermore, OPTN shows a unique aggregation pattern compared to other disease-related proteins in yeast. OPTN aggregates co-localize only partially with the Insoluble Protein Deposit site (IPOD) markers, but coincide perfectly with the prion seed-reducing protein Btn2 and several other aggregation-prone proteins, suggesting that protein aggregates are not limited to a single IPOD site. Importantly, changes in the Btn2p level modify OPTN toxicity and aggregation. This study generates a mechanistic framework for investigating how OPTN may trigger pathological changes in ALS and other OPTN-linked neurodegenerative disorders.
    Full-text · Article · Oct 2012 · Molecular Microbiology
Show more